New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: A report from the Children's Oncology Group
ÌÇÐÄ´«Ã½
Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: A report from the Children's Oncology Group PEDIATRIC BLOOD & CANCER Raney, B., Huh, W., Hawkins, D., Hayes-Jordan, A., Million, L., Rodeberg, D., Teot, L., Anderson, J. 2013; 60 (3): 371-376Abstract
We wanted to ascertain patterns of recurrence, re-treatment, and outcome among 188 eligible patients treated for localized orbital sarcoma on IRSG Protocols III/IV, 1984-1997.Retrospective chart review.Twenty-four of 188 patients (12.8%) developed local (n?=?22) or distant relapse (n?=?2) at 0.057-7.05 years (median, 1.58) after enrollment. Ages at study entry were 0.14-17 years (median, 5 years). Initial tumor operations included biopsy (n?=?20) or gross resection with microscopic residual (n?=?4). Initial tumor diameters were 0.5-7?cm (median, 3). Pathologic subtypes were embryonal rhabdomyosarcoma (ERMS, n?=?19), sarcoma not otherwise specified (n?=?2), and alveolar RMS, botryoid ERMS, or undifferentiated sarcoma (n?=?1 each). Initial treatment included vincristine/dactinomycin (n?=?24) including an alkylator (n?=?4) and radiotherapy (RT, n?=?21). Twenty patients responded, 14 completely, 6 partially. After recurrence, patients underwent orbital exenteration (n?=?10), enucleation (2), tumor excision (3), or biopsy (1); 7 had no operation, and 1 had no data. Post-relapse chemotherapy included combinations of etoposide (n?=?14 patients), doxorubicin (14), ifosfamide (12), cyclophosphamide (7), and dacarbazine (n?=?1). Six patients received RT, including four previously treated and two not irradiated initially. Two patients died; one at 1.79 years after contralateral brain metastasis followed by local recurrence, and another at 2.49 years after multiple local recurrences. Twenty-two patients (91.7%) survived sarcoma-free for 0.04-17 years (median, 6.9) after relapse, and 18 of 22 (82%) were alive =5 years after relapse.Survival following recurrent localized orbital sarcoma appears likely after vigorous re-treatment given with curative intent.
View details for
View details for
View details for